Our findings also provide useful insights into the comprehension of BRAF<sup>V600E</sup>-driven malignancies pathophysiology as well as the consequences in vivo of novel ERK pathway-targeted anti-cancer therapies. The gene discussed is MAPK1; the disease is cancer.